Offers for 23 innovative drugs arrive – State sets aside RSD 996.5 million

The procedure of public procurement of 23 innovative drugs is currently in progress at the National Health Insurance Fund, and the majority of them will become available in hospitals and pharmacies in the next few days.

NHIF says that the the decision on putting 23 innovative drugs on the reimbursement list, after being adopted by the Government of Serbia, came into effect on December 17, 2016, and that they immediately initiated the public procurement procedure so that modern therapy would reach patients as soon as possible.

The opening of bids took place on January 12, and decision on signing framework agreements was made a day later.

The majority of drugs received one bid each, and the signing of the framework agreements with the suppliers is expected in the next few days, said acting director of NHIF, Verica Lazic.

Four drugs received several bids and the signing of framework agreements with suppliers is expected after the expiration of the deadline period of 10 days for filing potential complaints.

A total of RSD 996.5 million has been set aside for the procurement of 23 innovative drugs in 2017.

Republički fond za zdravstveno osiguranje Beograd

National Helath Insurance Fund

NHIF

Verica Lazic

innovative drugs

drugs for grave pediatrics diseases

drugs for transplant patients

drugs for grave hematological diseases

drugs for grave oncology diseases

drugs for grave diseases in children

mandatory health insurance

innovative drug manufacturers

hematology

transplants

oncology

pediatrics

original drugs